| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
We examined the reno-protective effects of SGLT2 inhibitors and its mechanism. Our data elucidated that the inhibitors for SGLT2 do not suppress the glucose uptake in the healthy proximal tubular cells, and that it does in the injured tubular cells. The kinetics of glucose uptake depends on GLUT2 that could be downregulated by the damage. The cells suppressed extracellular glucose uptake by the combination with cell damage and SGLT2 inhibition, upregulated angiogenic factors, such as VEGFA. This contributed to the reconstruction of capillary network in the kidney. The glucose uptake in the proximal tubules was unaffected even under the hyperglycemic or hypoglycemic condition, by SGLT2 inhibitor treatment.
|
